Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-18T23:03:03.676Z Has data issue: false hasContentIssue false
  • English
  • Français

Kidney-specific proteins in patients receiving aprotinin at high- and low-dose regimens during coronary artery bypass graft with cardiopulmonary bypass

Published online by Cambridge University Press:  26 August 2005

A. Faulí ,
C. Gomar ,
J. M. Campistol ,
L. Álvarez ,
A. M. Manig  and
P. Matute
A. Faulí
Affiliation:
University of Barcelona, Hospital Clínic, Department of Anesthesiology, Barcelona, Spain
C. Gomar
Affiliation:
University of Barcelona, Hospital Clínic, Department of Anesthesiology, Barcelona, Spain
J. M. Campistol
Affiliation:
University of Barcelona, Hospital Clínic, Department of Nephrology, Barcelona, Spain
L. Álvarez
Affiliation:
University of Barcelona, Hospital Clínic, Department of Biochemistry Laboratory, Barcelona, Spain
A. M. Manig
Affiliation:
University of Barcelona, Hospital Clínic, Department of Research and Development Board, Barcelona, Spain
P. Matute
Affiliation:
University of Barcelona, Hospital Clínic, Department of Anesthesiology, Barcelona, Spain
Get access

Extract

Summary

Background and objective: The aim was to determine whether the administration of aprotinin can cause deleterious effects on renal function in cardiac surgery with cardiopulmonary bypass (CPB). Methods: Sixty consecutive patients with normal preoperative renal function undergoing elective coronary artery bypass surgery with CPB using the same anaesthetic; CPB and surgical protocols were randomized into three groups. Patients received placebo (Group 1), low-dose aprotinin (Group 2) or high-dose aprotinin (Group 3). Renal parameters measured were plasma creatinine, α1-microglobulin and β-glucosaminidase (β-NAG) excretion. Measurements were performed before surgery, during CPB and 24 and 72 h, and 7 and 40 days postoperatively. Results: In the three groups, α1-microglobulin and β-NAG excretions significantly increased during CPB, at 24 and 72 h, and 7 days postoperatively (P < 0.05) and had returned to preoperative levels at postoperative day 40. Plasma creatinine levels were within normal values at times recorded. In Groups 2 and 3, α1-microglobulin excretion during CPB was significantly higher than in Group 1 (P < 0.001), and 24 h after surgery it still remained significantly higher in Group 3 compared to Groups 1 and 2 (P < 0.05). Conclusions: Aprotinin caused a significant increase in α1-microglobulin excretion but not in β-NAG excretion during CPB, which may be interpreted as a greater renal tubular overload without tubular damage. This effect persisted for 24 h after surgery when high-dose aprotinin doses had been administered. Creatinine plasma levels were not sensitive to detect these prolonged renal effects in our study.

Keywords

APROTININKIDNEY FUNCTION TESTS, α1-microglobulin, β-glucosaminidaseCORONARY ARTERY BYPASSCARDIOPULMONARY BYPASS
Type
Original Article
Information
European Journal of Anaesthesiology , Volume 22 , Issue 9 , September 2005 , pp. 666 - 671
Copyright
© 2005 European Society of Anaesthesiology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. Ann Intern Med 1998; 128: 194–203.Google Scholar
Kulka PJ, Tryba M, Zenz M. Preoperative alpha2-adrenergic receptor agonists prevent the deterioration of renal function after cardiac surgery: results of the randomized, controlled trial. Crit Care Med 1996; 24: 947–952.Google Scholar
Louagie YA, Gonzalez M, Collard E et al. Does flow character of cardiopulmonary bypass make a difference? J Cardiovasc Surg 1992; 104: 1628–1638.Google Scholar
Urzua J, Troncoso S, Bugedo G et al. Renal function and cardiopulmonary bypass: effects of perfusion pressure. J Cardiovasc Anesth 1992; 6: 299–303.Google Scholar
Mantur M, Kemona H, Dabrowsky W, Dabrowska J, Sobolewski S, Prokopowicz J. Alpha1-microglobulin as a marker of proximal tubular damage in urinary tract infection in children. Clin Nephrol 2000; 53: 283–287.Google Scholar
Jung K, Becker S. Multiple forms of N-acetyl-beta-d-glucosaminidase of human urine: isolation, properties and the development of a practical approach of differentiation. Biomed Biochim Acta 1991; 50: 861–867.Google Scholar
Mazzarella V, Gallucci T, Tozzo C et al. Renal function in patients undergoing cardiopulmonary bypass operations. J Thorac Cardiovasc Surg 1992; 104: 1625–1627.Google Scholar
Faulí A, Gomar C, Campistol JM, Alvarez L, Manig AM, Matute P. Pattern of renal dysfunction associated with myocardial revascularization surgery and cardiopulmonary bypass. Eur J Anaesthesiol 2003; 20: 443–450.Google Scholar
Royston D. High-dose aprotinin therapy: a review of first five years' experience. J Cardiothorac Vasc Anesth 1992; 6: 76–100.Google Scholar
Lemmer Jr JH, Stanford W, Bonney SL et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg 1994; 107: 543–551.Google Scholar
Rustom R, Grime S, Maltby P, Stockdale HR, Critchley M, Bone JM. A new method to measure renal tubular degradation of small filtered proteins in man using radiolabelled aprotinin (Trasylol). Clin Sci 1992; 82: 289–294.Google Scholar
Bidstrup BP, Harrison J, Royston D, Taylor KM, Treasure T. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993: 55: 971–976.Google Scholar
Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P. Effects of high-dose aprotinin blood loss, platelet function, fibrinolysis, complement and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 101: 958–967.Google Scholar
Lemmer Jr JH, Stanford W, Bonney SL et al. Aprotinin for coronary artery bypass grafting: effects on postoperative renal function. Ann Thorac Surg 1995; 59: 132–136.Google Scholar
Feindt PR, Walcher S, Volkmer I et al. Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting. Ann Thorac Surg 1995; 60: 1076–1080.Google Scholar
Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effects of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 5: 1289–1291.Google Scholar
Boldt J, Brenner T, Lang J, Kumle B, Isgro F. Kidney- specific proteins in elderly patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth Analg 2003; 97: 1582–1589.Google Scholar
Ascione R, Lloyd CT, Underwood MJ, Gomes WJ, Angelini GD. On-pump versus off-pump coronary revascularization: evaluation of renal function. Ann Thorac Surg 1999; 68: 493–498.Google Scholar
Dietrich W, Barankay A, Hahnel C, Richter JA. High dose aprotinin in cardiac surgery: three years' experience in 1,784 patients. J Cardiothorac Vasc Anesth 1992; 6: 324–327.Google Scholar